Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
1.
Curr Oncol ; 27(3): e332-e335, 2020 06.
Article in English | MEDLINE | ID: covidwho-646931

ABSTRACT

The emergence of the covid-19 disease pandemic caused by the 2019 novel coronavirus has required a re-evaluation of treatment practices for clinicians caring for patients with chronic lymphocytic leukemia (cll). The American Society for Hematology (ash) has provided a series of recommendations for the treatment of patients with cll during the pandemic, covering a range of topics, including testing for covid-19, cll treatment initiation and selection, use of immunoglobulin therapy, in-person monitoring, and treatment of patients with cll and covid-19. We summarize the ash recommendations and discuss their applicability as guidelines for the treatment of cll during the covid-19 pandemic in Canada.


Subject(s)
Antineoplastic Agents/therapeutic use , Coronavirus Infections/epidemiology , Immunologic Factors/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Pneumonia, Viral/epidemiology , Adenine/analogs & derivatives , Ambulatory Care/methods , Appointments and Schedules , Betacoronavirus , COVID-19 , Canada/epidemiology , Coronavirus Infections/complications , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Disease Management , Hospitalization , Humans , Immunoglobulins, Intravenous/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Pandemics , Piperidines , Pneumonia, Viral/complications , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , Practice Guidelines as Topic , Pyrazoles/therapeutic use , Pyrimidines/therapeutic use , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL